This inventor holds 1 USPTO granted patent and 1 published patent application, plus 1 CIPO patent and 2 EPO patents. Top assignee: Sbi Pharmaceuticals Co., Ltd.. Active years: 2015.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2015
Title: Takahiro Masubuchi: Innovator in Mitochondrial Dysfunction Treatments
Introduction
Takahiro Masubuchi is a notable inventor based in Yamatokooriyama, Japan. He has made significant contributions to the field of medical science, particularly in the treatment of mitochondrial dysfunction brain diseases. His innovative approach has led to the development of therapeutic and diagnostic agents that address critical health issues.
Latest Patents
Masubuchi holds a patent for a therapeutic agent and diagnostic agent for mitochondrial dysfunction brain diseases. This patent, which includes a combination of δ-aminolevulinic acid and an iron compound, aims to provide effective treatment options for conditions such as cerebral infarction. The patent highlights the importance of these compounds in addressing mitochondrial dysfunction, which is crucial for brain health.
Career Highlights
Throughout his career, Masubuchi has been associated with Sbi Pharmaceuticals Co., Ltd., where he has focused on research and development in the pharmaceutical sector. His work has been instrumental in advancing therapeutic options for patients suffering from complex brain diseases.
Collaborations
Masubuchi has collaborated with esteemed colleagues, including Toshihiko Kuroiwa and Yoshinaga Kajimoto. These partnerships have fostered a collaborative environment that enhances innovation and research in the field of pharmaceuticals.
Conclusion
Takahiro Masubuchi's contributions to the treatment of mitochondrial dysfunction brain diseases exemplify the impact of innovative thinking in medical science. His patent and collaborative efforts continue to pave the way for advancements in therapeutic solutions.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile